SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients

Aileen X. Wang,1 Stephan Busque,2 Jamie Kuo,3 Upinder Singh,4,5 Katharina Rööeltgen,6 Benjamin A. Pinsky,2,6 Glenn M. Chertow,1,7 John D. Scandling,1 and Colin R. Lenihan1

Key Points
- Early outpatient severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mAb treatment of coronavirus disease 2019 (COVID-19) in kidney transplant recipients was safe and well tolerated.
- COVID-19–related hospitalizations were fewer in the mAb group despite having greater risk factors for disease progression.
- Angiotensin-converting enzyme 2 receptor blocking activity of anti–SARS-CoV-2 IgG acquired from natural immunity was weak on initial and follow-up serology testing.

Abstract
Background Morbidity and mortality associated with coronavirus disease 2019 (COVID-19) infection in kidney transplant recipients are high and early outpatient interventions to prevent progression to severe disease are needed. SARS-CoV-2 neutralizing mAbs, including bamlanivimab and casirivimab-imdevimab, received emergency use authorization in the United States in November 2020 for treatment of mild to moderate COVID-19 disease.

Methods We performed a retrospective analysis of 27 kidney transplant recipients diagnosed with COVID-19 between July 2020 and February 2021 who were treated with bamlanivimab or casirivimab-imdevimab and immunosuppression reduction. We additionally identified 13 kidney transplant recipients with COVID-19 who had mild to moderate disease at presentation, who did not receive mAbs, and had SARS-CoV-2 serology testing available.

Results There were no deaths or graft failures in either group. Both infusions were well tolerated. Four of the 27 patients treated with mAbs required hospitalization due to COVID-19. Four of 13 patients who did not receive mAbs required hospitalization due to COVID-19. Patients who received mAbs demonstrated measurable anti–SARS-CoV-2 IgG with angiotensin-converting enzyme 2 (ACE2) receptor blocking activity at the highest level detectable at 90 days postinfusion, whereas ACE2 blocking activity acquired from natural immunity in the mAb-untreated group was weak.

Conclusions Bamlanivimab and casirivimab-imdevimab combined with immnosuppression reduction were well tolerated and associated with favorable clinical outcomes in kidney transplant recipients diagnosed with mild to moderate COVID-19.

Introduction
Advances in supportive care and the identification of effective therapeutics have contributed to improved outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19) (1,2). However, kidney transplant recipients remain at higher risk for COVID-19–associated complications and mortality (3,4). Compared with matched nontransplant patients, kidney transplant recipients experience a doubling of risk of COVID-19–related death after adjusting for age, body...
mass index, and other major comorbidities (5). Therefore, the identification of early interventions that can halt the progression from mild or moderate to severe COVID-19 is especially important in this vulnerable population.

Although there are several inpatient therapies, such as remdesivir, dexamethasone, tocilizumab, and baricitinib, that are available to treat patients with COVID-19 that require hospitalization, there are few outpatient therapeutic options for early intervention that could prevent the progression to severe disease. Like most transplant centers, we modify immunosuppression in kidney transplant recipients with COVID-19 (6). Our practice has been to reduce immunosuppression, usually by holding the immunosuppressant immediately upon COVID-19 diagnosis (7). Since December 2020, we treated eligible kidney transplant recipients positive for COVID-19 with bamlanivimab. The increasing prevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant CAL.20C in our region later prompted a change in our mAb treatment regimen from bamlanivimab to casirivimab-imdevimab in February 2021 (8).

Bamlanivimab is an mAb that binds with high affinity to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein on the viral surface. Casirivimab-imdevimab is a cocktail containing noncompeting, neutralizing human IgG1 antibodies that can bind simultaneously to different, nonoverlapping epitopes of the spike protein. Both drugs prevent virus entry into host cells by blocking the binding of the spike protein to the cell surface angiotensin-converting enzyme 2 (ACE2) receptor (9). On November 9, 2020, bamlanivimab received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for treatment of mild to moderate COVID-19 in outpatients at high risk of progressing to severe disease within 10 days of symptom onset (10). Casirivimab-imdevimab subsequently received EUA from the FDA later on November 21, 2020 (11). The European Medicine Agency’s Committee for Medicinal Products for Human Use granted conditions of use for casirivimab-imdevimab and bamlanivimab on February 26 and March 5, 2021, respectively (12,13).

Here, we report our experience with bamlanivimab and casirivimab-imdevimab infusions combined with immunosuppression reduction for the treatment of COVID-19 in kidney transplant recipients.

Materials and Methods
We performed a retrospective analysis of kidney transplant recipients who were diagnosed with COVID-19 between July 2020 and February 2021. Demographic and clinical data were abstracted by review of electronic health records.

Patients
We abstracted data on kidney transplant recipients with COVID-19 who received treatment with either bamlanivimab or casirivimab-imdevimab under EUA. For comparison, data were also abstracted from kidney transplant recipients with mild to moderate COVID-19 at presentation who did not receive mAb treatment and had SARS-CoV-2 serology testing available. All patients had a functioning kidney transplant. Those who were on an antimetabolite (mycophenolate mofetil/mycophenolate sodium/azathioprine) were instructed to hold it at the time of COVID-19 diagnosis. Patients were eligible to receive either bamlanivimab (before February 10, 2021) or casirivimab-imdevimab (after February 10, 2021) if they met the FDA’s EUA criteria (14), as outlined in Supplemental Table 1.

Diagnostic Testing
SARS-CoV-2 RT-PCR testing was performed on nasopharyngeal swab samples (Stanford Clinic Virology Laboratory) (15). IgM and IgG antibodies to the SARS-CoV-2 spike RBD were measured by ELISA. In patients with positive anti-SARS-CoV-2 IgG, the ability of the anti-SARS-CoV-2 IgG to block the binding of the SARS-CoV-2 RBD to the cell surface ACE2 receptor was assessed using an RBD-ACE2 competition ELISA developed by the Stanford Department of Pathology (16). This assay was developed as a functional assay to assess the quality, rather than the quantity, of antibodies against SARS-CoV-2. It has been compared with both the anti-RBD IgG assays and pseudovirus neutralization assays, and a strong correlation among them has been shown. The RBD-ACE2 competition assay is reported as a percentage of the SARS-CoV-2 RBD to ACE2 receptor blocking activity, where 0%-10% indicates the presence of little to no antibody blocking activity (comparable with a sample from an individual who has never been exposed to SARS-CoV-2), and 90%-100% indicates a high level of blocking activity.

Administration
Bamlanivimab and casirivimab-imdevimab were administered as a single outpatient intravenous infusion of 700 and 2400 mg, respectively, in 200–270 ml normal saline over 60 minutes with a 0.2–0.22 μm in-line polysulfone filter. All patients were monitored during infusion and for 1 hour after the infusion.

Statistical Analysis
Data are shown as numbers (percentages) for categoric variables and as medians (interquartile ranges [IQR]) for continuous variables.

This study was approved by the Stanford University Institutional Review Board (protocol number 59887, consent waiver). The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.

Results
Between July 2020 and February 2021, 27 patients met the EUA criteria (Supplemental Table 1) and received either bamlanivimab or casirivimab-imdevimab between December 2020 and February 2021. Thirteen patients who did not receive neutralizing antibody but had serologic data available were selected as the comparison group. Of these, seven patients met EUA criteria but did not receive either bamlanivimab or casirivimab-imdevimab due to their unavailability, five patients did not meet EUA criteria (had
Table 1. Patient demographic and clinical characteristics

| Patient | Age (to Nearest Decade) | Lymphocyte-Depleting Therapy | Body Mass Index, kg/m² | Diabetes Mellitus | Number of Other High-Risk Factors | Maintenance Immunosuppression | Mycophenolate Mofetil Held, days | Symptom Onset to Diagnosis, days | Cycle Threshold of SARS-CoV-2 RT-PCR, days | Symptom Onset to Infusion, days | Hospitalized mAb | <1 Year Transplant |
|---------|--------------------------|-------------------------------|------------------------|------------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|-------------------------------|-----------------|------------------|
| 1       | 40                       | ATG                           | 35.4                   | M                | N                               | MMF/Tac                       | 8                             | 0                             | —                               | 3                | N                | Bam             |
| 2       | 30                       | ATG                           | 41.3                   | F                | N                               | MMF/Tac/Pred                  | 20                            | 0                             | —                               | 8                | N                | Bam             |
| 3       | 50                       | ATG                           | 32.0                   | F                | Y                               | MMF/Tac/Pred                  | 9                             | 2                             | 38.0                           | 9                | N                | Bam             |
| 4       | 40                       | ATG                           | 27.3                   | M                | Y                               | MMF/Tac                       | 25                            | (−2)                          | 30.4                           | 6                | Y                | Bam             |
| 5       | 70                       | ATG                           | 26.7                   | F                | Y                               | MMF/Tac/Pred                  | 13                            | 1                             | —                               | 5                | N                | Bam             |
| 6       | 40                       | ATG/OBZ                       | 28.5                   | M                | N                               | MMF/Tac/Pred                  | 16                            | (−1)                          | —                               | 5                | N                | Bam             |
| 7       | 50                       | ATG/RTX                       | 29.2                   | F                | Y                               | MMF/Tac/Pred                  | 16                            | 7                             | —                               | 9                | N                | Bam             |
| 8       | 50                       | ATG                           | 21.7                   | M                | N                               | MMF/Tac/Pred                  | 13                            | (−2)                          | —                               | 1                | N                | Bam             |
| 9       | 30                       | ATG                           | 30.4                   | M                | N                               | MMF/Tac/Pred                  | 13                            | 2                             | —                               | 5                | N                | Bam             |
| 10      | 80                       | ATG/RTX                       | 25.6                   | F                | N                               | MMF/Tac/Pred                  | 17                            | 0                             | —                               | 3                | N                | Bam             |
| 11      | 60                       | ATG                           | 23.5                   | F                | N                               | MMF/Tac/Pred                  | 13                            | 2                             | 17.3                           | 8                | N                | Bam             |
| 12      | 70                       | ATG                           | 19.4                   | F                | N                               | MMF/Tac                       | 12                            | 2                             | —                               | 4                | N                | Bam             |
| 13      | 40                       | ATG/RTX                       | 31.5                   | F                | N                               | MMF/Tac/Pred                  | 14                            | 1                             | 15.7                           | 3                | N                | Bam             |
| 14      | 60                       | ATG                           | 30.0                   | M                | N                               | MMF/Tac/Pred                  | 17                            | 3                             | —                               | 5                | N                | Bam             |
| 15      | 30                       | ATG/RTX                       | 39.7                   | F                | N                               | MMF/Tac/Pred                  | 17                            | 3                             | —                               | 5                | N                | Bam             |
| 16      | 40                       | —                             | 23.2                   | M                | Y                               | MMF/Tac                       | 18                            | 7                             | —                               | 9                | N                | Bam             |
| 17      | 50                       | ATG                           | 30.5                   | M                | Y                               | MMF/Tac/Pred                  | 9                             | 2                             | 15.6                           | 2                | N                | Bam             |
| 18      | 30                       | ATG                           | 30.1                   | M                | N                               | MMF/Tac/Pred                  | 13                            | 0                             | —                               | 3                | N                | Bam             |
| 19      | 70                       | ATG                           | 33.3                   | F                | N                               | MMF/Tac/Pred                  | 1                            | —                             | 7                               | N                | N                | Bam             |
| 20      | 70                       | —                             | 26.0                   | M                | N                               | MMF/Tac/Pred                  | 8                             | 1                             | —                               | 8                | N                | Bam             |
| 21      | 60                       | ATG                           | 28.1                   | M                | N                               | MMF/Tac                       | 13                            | 3                             | —                               | 6                | N                | CASIM           |
| 22      | 50                       | ATG                           | 21.1                   | F                | N                               | MMF/Tac/Pred                  | 12                            | (−1)                          | —                               | 4                | N                | CASIM           |
| 23      | 30                       | ATG                           | 26.8                   | M                | N                               | MMF/Tac/Pred                  | 20                            | 2                             | —                               | 3                | N                | CASIM           |
| 24      | 60                       | ATG                           | 23.5                   | M                | Y                               | MMF/Tac/Pred                  | 10                            | 1                             | —                               | 4                | N                | CASIM           |
| 25d     | 30                       | ATG                           | 22.8                   | F                | N                               | MMF/Tac                       | 11                            | 6                             | —                               | 10               | N                | CASIM           |
| 26      | 60                       | ATG                           | 25.2                   | F                | N                               | MMF/Tac/Pred                  | 12                            | 5                             | —                               | 7                | Y                | CASIM           |
| 27d     | 50                       | ATG/RTX                       | 21.6                   | M                | Y                               | MMF/Tac/Pred                  | 16                            | 8                             | —                               | 10               | Y                | CASIM           |

No mAb (N=13)

| Patient | Age (to Nearest Decade) | Lymphocyte-Depleting Therapy | Body Mass Index, kg/m² | Diabetes Mellitus | Number of Other High-Risk Factors | Maintenance Immunosuppression | Mycophenolate Mofetil Held, days | Symptom Onset to Diagnosis, days | Cycle Threshold of SARS-CoV-2 RT-PCR, days | Symptom Onset to Infusion, days | Hospitalized mAb | <1 Year Transplant |
|---------|--------------------------|-------------------------------|------------------------|------------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|-------------------------------|-----------------|------------------|
| 1       | 60                       | ATG                           | 25.8                   | F                | Y                               | MMF/Tac/Pred                  | 48                            | 14                            | —                               | 26.6                         | —               | N                |
| 2       | 30                       | ATG/RTX                       | 26.7                   | F                | N                               | MMF/Tac                       | 14                            | 5                             | 26.6                           | —               | N                | N                |
| 3       | 60                       | ATG                           | 31.7                   | M                | Y                               | MMF/Tac                       | 14                            | 5                             | 16.5                           | —               | N                | N                |
| 4       | 20                       | ATG/RTX                       | 30.2                   | F                | N                               | MMF/Tac                       | 14                            | 5                             | 26.6                           | —               | N                | N                |
| 5       | 20                       | ATG/ALZ                       | 20.2                   | F                | N                               | MMF/Tac/Pred                  | 14                            | 0                             | 28.4                           | —               | N                | Y                |
| 6       | 50                       | ATG                           | 29.7                   | F                | N                               | MMF/Tac/Pred                  | 23                            | 4                             | —                               | —               | N                | N                |
| 7       | 30                       | ATG/RTX                       | 24.8                   | M                | N                               | MMF/Tac/Pred                  | 14                            | 1                             | 22.9                           | —               | N                | N                |
| 8       | 50                       | ATG                           | 26.4                   | M                | N                               | MMF/Tac                       | 14                            | 14                            | —                               | —               | N                | N                |
| Patient | Age (to Nearest Decade) | Lymphocyte-Depleting Therapy | Body Mass Index, kg/m² | Sex | Diabetes Mellitus | Number of Other High-Risk Factors | Maintenance Immunosuppression | Symptom Onset to Diagnosis, days | Cycle Threshold of SARS-CoV-2 RT-PCR | Symptom Onset to Infusion, days | Hospitalized | mAb | <1 Year Transplant |
|---------|-------------------------|-------------------------------|------------------------|-----|------------------|---------------------------------|-----------------------------|-------------------------------|---------------------------------|---------------------------------|--------------|-----|------------------|
| 9       | 50                      | ATG                           | 33.3                   | M   | N                | 0                               | MMF/Tac/Pred                | 17                             | 3                              | 23.3                            | —             | Y  | —                |
| 10      | 50                      | ATG                           | 35.1                   | F   | N                | 1                               | MMF/Tac                     | 11                             | 3                              | —                               | —             | Y  | —                |
| 11      | 40                      | ATG                           | 34.0                   | F   | N                | 0                               | AZA/Tac/Pred                | 7                              | 11                             | —                               | —             | N  | —                |
| 12      | 60                      | ATG                           | 29.2                   | F   | N                | 0                               | MMF/Tac                     | —                             | 2                              | —                               | —             | N  | —                |
| 13      | 30                      | ATG/RTX                       | 25.5                   | F   | N                | 0                               | MMF/Tac/Pred                | 7                              | 10                             | —                               | —             | N  | —                |

MMF, mycophenolate mofetil; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ATG, antithymocyte Ig; M, male; N, no; Tac, tacrolimus; —, no data available/applicable; Bam, bamlanivimab; Y, yes; F, female; Pred, prednisone; OBZ, obinutuxumab (anti-CD20); RTX, rituximab (anti-CD20); CASIM, casirivimab-imdevimab; ALZ, alemtuzumab (anti-CD52); AZA, azathioprine.

aIn addition to immunocompromised state, including BMI $\geq$35 kg/m², diabetes mellitus, age $\geq$65 years, and/or chronic respiratory disease.

bData not available for all patients due to testing done at outside facilities.

cDelayed.

dReceived full vaccination series before positive diagnosis.
symptoms present for >10 days), and one patient declined bamlanivimab treatment despite meeting EUA eligibility.

Demographic and clinical characteristics of both groups are shown in Table 1 and Table 2. Those in the mAb group had a shorter median time from transplant to SARS-CoV-2 infection, with a numerically higher number of risk factors for progression to severe COVID-19 as defined by the EUA. The median (IQR) time from COVID-19 symptom onset to positive diagnosis was two (1–3) days for the mAb group, with four patients developing symptoms after a positive SARS-CoV-2 RT-PCR test (Table 1). Mycophenolate mofetil/mycophenolate sodium/azathioprine was held for a similar duration of time between the two groups. The median (IQR) time from COVID-19 symptom onset to mAb treatment was five (3–8) days.

There were no deaths or graft failures in either group. After receiving bamlanivimab, one patient complained of transient and self-limiting chest tightness and another of headache; both resolved within 24 hours after the infusion.

### Table 2. Summary of patient characteristics

| Characteristics                                      | mAb (N=27) ^a | No mAb (N=13) |
|------------------------------------------------------|---------------|---------------|
| Age, yr, median (IQR)                                | 52 (37–61)    | 44 (32–54)    |
| Female, n (%)                                        | 12 (44)       | 9 (69)        |
| BMI, kg/m^2, median (IQR)                            | 26.7 (23.2–30.5) | 29.2 (25.7–32.5) |
| Diabetes, n (%)                                      | 8 (30)        | 2 (15)        |
| Race, n (%)                                          |               |               |
| White (Non-Hispanic)                                 | 7 (26)        | 2 (15)        |
| Hispanic                                             | 9 (33)        | 10 (77)       |
| Black透 | 1 (4)         | 0             |
| Asian or Pacific Islander                            | 10 (37)       | 1 (8)         |
| Within 1-yr transplant, n (%)                        | 8 (30)        | 1 (8)         |
| Time from transplant, mo, median (IQR)               | 22 (8–68)     | 49 (26–63)    |
| Number of additional high-risk factors, n (%) ^b     |               |               |
| 0                                                    | 11 (41)       | 10 (77)       |
| 1                                                    | 14 (52)       | 3 (23)        |
| ≥2                                                   | 2 (7)         | 0             |
| Lymphocyte-depleting therapy, n (%)                  | 25 (93)       | 13 (100)      |
| ATG/anti-CD52 within 1 yr                            | 0             | 1 (8)         |
| Anti-CD20 within 1 yr                                | 5 (19)        | 4 (31)        |
| Maintenance immunosuppression, n (%)                 |               |               |
| MMF/Tac/Pred                                        | 18 (67)       | 7 (54)        |
| MMF/Tac                                             | 6 (22)        | 4 (31)        |
| Other                                                | 3 (11)        | 2 (15)        |
| Duration of MMF/MPA/AZA held, d, median (IQR)        | 13 (11–17)    | 14 (8–17)     |
| Symptoms, n (%)                                      |               |               |
| Fever                                                | 12 (44)       | 6 (46)        |
| Cough                                                | 17 (63)       | 7 (54)        |
| Muscle pain                                          | 12 (44)       | 5 (39)        |
| Headache                                             | 11 (41)       | 2 (15)        |
| Fatigue                                              | 7 (26)        | 6 (46)        |
| Gastrointestinal                                     | 11 (41)       | 5 (39)        |
| Shortness of breath                                  | 4 (15)        | 3 (23)        |
| Loss of sense of taste/smell                          | 2 (7)         | 3 (23)        |
| Other (poor appetite, congestion, chest pressure, chills) | 9 (33)        | 6 (46)        |
| Symptom onset to diagnosis, d, median (IQR)          | 2 (1–3)       | 5 (3–11)      |
| Symptom onset to initial serology, d, median (IQR)   | 5 (3–8)       | 18 (13–29)    |
| Diagnosis to initial serology, d, median (IQR)       | 3 (2–6)       | 13 (9–19)     |
| Ct values, median (IQR) ^c                           | 17.3 (15.7–34.2) | 23.3 (19.7–27.5) |
| AKI, n (%)                                           | 7 (26)        | 4 (31)        |
| Symptom onset to infusion, d, median (IQR)           | 5 (3–8)       | —             |

Categoric variables are presented as numbers (percentages). Continuous variables as medians (interquartile ranges). IQR, interquartile range; BMI, body mass index; ATG, antithymocyte Ig; anti-CD52, alemtuzumab; anti-CD20, obinutuximab, rituximab; MMF, mycophenolate mofetil; tac, tacrolimus; pred, prednisone; MPA, mycophenolic acid; AZA, azathioprine; Ct, cycle threshold of SARS-CoV-2 RT-PCR tests; —, no data available/applicable.

^aBamlanivimab or casirivimab-imdevimab.

^bBody mass index ≥35 kg/m^2, diabetes mellitus, age ≥65 years, and/or chronic respiratory disease.

^cN=5 for each group.
imdevimab developed reactions. Four patients who received mAbs were subsequently hospitalized (two after receiving bamlanivimab and two after receiving casirivimab-imdevimab). Two were hospitalized with COVID-19 pneumonia later on the same day that they received their mAb treatment. One did not require intensive care and recovered to discharge after 3 days. The other patient did require monitoring in intensive care while on high-flow oxygen therapy but recovered to discharge on room air after 6 days. The third patient was admitted to hospital 3 days after bamlanivimab infusion with a foot cellulitis that was deemed unrelated to COVID-19. The fourth patient was admitted to hospital the day after receiving casirivimab-imdevimab with volume depletion and AKI in the setting of nausea, vomiting, and diarrhea. Four patients in the comparison group were hospitalized due to COVID-19. One was hospitalized for severe diarrhea and AKI. Three patients were admitted for acute hypoxic respiratory failure due to COVID-19 pneumonia about 1 week after symptom onset, with two out of the three patients requiring intensive care. Seven patients in the mAb group and four patients in the comparison group had AKI, which was defined as an elevation in serum creatinine either 1.5 times baseline or 0.3 mg/dl above baseline (17). AKI episodes were considered prerenal in the setting of COVID-19 gastrointestinal upset, occasionally exacerbated by supratherapeutic tacrolimus levels, in the majority of patients. Serum creatinine returned to baseline in all patients. There were no biopsy sample–proven rejections in either of the two groups. The trends in creatinine for all patients in both groups are illustrated in Table 3.

Initial and follow-up anti-SARS-CoV-2 IgM and IgG details are shown in Table 4 and Figure 1. In the mAb group, all but one patient with available pretreatment serology testing were anti-SARS-CoV-2 IgG seronegative (23 of 24 patients). Three patients did not have a pretreatment “baseline” anti-SARS-CoV-2 serology because blood work was inadvertently drawn immediately after infusion. Twenty-three patients had post-mAb serologies available, and all were anti-SARS-CoV-2 IgG seropositive with strong ACE2 receptor blocking activity. Seventeen of the 23 patients remained anti-SARS-CoV-2 IgM seronegative. Two of the 23 patients had further serologic testing up to 83 and 95 days post-treatment, which showed persistence of anti-SARS-CoV-2 IgG with strong ACE2 receptor blocking activity (Figure 1 and Table 4). In the comparison group, six of the 13 patients were seropositive for both IgM and IgG on initial testing, at a median (IQR) of 14 (11–19) days after diagnosis. One of the 13 patients was seropositive for IgG only on initial testing at 115 days after diagnosis. Five of the six patients who were seronegative on initial testing seroconverted on later testing at a median (IQR) of 40 (22–94) days after diagnosis. At both initial and follow-up testing, ACE2-blocking anti-SARS-CoV-2 IgG activity was weak in most patients who were not treated with mAbs.

**Discussion**

In this series, we found that bamlanivimab or casirivimab-imdevimab combined with immunosuppression reduction for outpatient treatment of mild to moderate COVID-19 in kidney transplant recipients was safe and associated with good outcomes. Only four of the 27 patients treated with mAbs required hospitalization for COVID-19. One of the 27 patients treated with mAbs required intensive care, whereas two of the 13 patients in the comparison group required intensive care. Hospitalization for COVID-19 complications was more frequent in the comparison group, despite fewer risk factors for disease progression than those treated with mAbs. The infusions of bamlanivimab and casirivimab-imdevimab were well tolerated. Only two of the 27 patients developed mild and self-limiting reactions postinfusion.

In the three clinical trials that have published findings on the use of SARS-CoV-2 neutralizing mAbs (bamlanivimab, casirivimab-imdevimab, and bamlanivimab-tesevimab) for outpatient treatment of mild to moderate COVID-19, solid-organ transplant recipients were excluded from the study cohort (18–20). Serologic testing after administration of SARS-CoV-2 neutralizing mAbs has also not been reported previously. Our findings are consistent with another US transplant centers’ reported experience of using bamlanivimab and casirivimab-imdevimab in a small number of solid-organ transplant recipients positive for COVID-19, where none of the recipients required hospitalization for disease progression (21,22). Furthermore, the availability at our center of a functional assay to evaluate the ACE2 receptor blocking activity of anti-SARS-CoV-2 IgG allowed comparison of passive immunity with bamlanivimab and casirivimab-imdevimab versus natural immunity, and its evolution over time. High ACE2 receptor blocking activity of anti-SARS-CoV-2 IgG is suggestive of greater viral inhibition and immunologic protection. All

**Table 3. AKI in mAb and no-mAb group**

| Characteristics                  | mAb (N=27) | No mAb (N=13) |
|----------------------------------|------------|---------------|
| AKI, n                           | 7          | 4             |
| Baseline creatinine, mean±SD     | 1.4±0.4b   | 1.0±0.2       |
| Creatinine at time of COVID-19 infection, mean±SD | 1.5±0.5b   | 1.3±0.3c       |
| Creatinine >2 weeks after COVID-19 infection, mean±SD | 1.3±0.3d   | 1.0±0.2       |

Categoric variables are presented as numbers. Continuous variables as mean±SD. COVID-19, coronavirus disease 2019.

*N=26.

*N=10.

*N=25.
| Patient | Symptoms Onset to Initial Serology, days | Diagnosis to Initial Serology, days | Initial SARS-CoV-2 IgM | Initial SARS-CoV-2 IgG | Angiotensin-Converting Enzyme 2 Blocking Activity, % | Next SARS-CoV-2 IgM | Next SARS-CoV-2 IgG | Angiotensin-Converting Enzyme 2 Blocking Activity, % | Time Between Serologies, days | Last SARS-CoV-2 IgM | Last SARS-CoV-2 IgG | Angiotensin-Converting Enzyme 2 Blocking Activity, % | Time from Initial Serology, days |
|---------|------------------------------------------|-----------------------------------|------------------------|-----------------------|--------------------------------------------|-------------------|-------------------|--------------------------------------------|-------------------------------|----------------|----------------|--------------------------------------------|-------------------------------|
| mAb (N=27) |                                         |                                    |                        |                        |                                            |                   |                   |                                            |                               |               |               |                                            |                               |
| 1       | 3                                        | 3                                 | Neg                    | Neg                   | —                                          | —                 | —                 | —                                          |                               |               |               |                                            |                               |
| 2       | 8                                        | 8                                 | Neg                    | Neg                   | —                                          | Neg               | Pos               | 90–100                                     | 95                            |               |               |                                            |                               |
| 3       | 9                                        | 7                                 | Pos                    | Pos                   | 90–100                                     | Pos               | Pos               | 90–100                                     | 7                             | Pos           | Pos           | 90–100                                     | 75                            |
| 4       | 6                                        | 8                                 | Neg                    | Neg                   | —                                          | Pos               | Pos               | 90–100                                     | 5                             | Pos           | Pos           | 90–100                                     | 21                            |
| 5       | 5                                        | 4                                 | Neg                    | Neg                   | Neg                                        | Neg               | Pos               | 90–100                                     | 10                            | Neg           | Pos           | 90–100                                     | 59                            |
| 6       | 5                                        | 6                                 | Neg                    | Neg                   | Pos                                        | Pos               | Pos               | 90–100                                     | 11                            | Pos           | Pos           | 90–100                                     | 58                            |
| 7       | 9                                        | 2                                 | Neg                    | Neg                   | Neg                                        | Pos               | 90–100                                     | 15                            | Neg           | Pos           | 90–100                                     | 41                            |
| 8       | 1                                        | 3                                 | Neg                    | Neg                   | Neg                                        | Pos               | Pos               | 90–100                                     | 9                             |               |               |                                            |                               |
| 9       | 5                                        | 3                                 | Neg                    | Neg                   | Neg                                        | Pos               | Pos               | 90–100                                     | 5                             |               |               |                                            |                               |
| 10      | 10                                       | 8                                 | Neg                    | Neg                   | Neg                                        | Neg               | Pos               | 90–100                                     | 9                             | Neg           | Pos           | 90–100                                     | 32                            |
| 11      | 3                                        | 3                                 | Neg                    | Neg                   | —                                          | —                 | —                 | —                                          |                               |               |               |                                            |                               |
| 12      | 8                                        | 6                                 | Neg                    | Neg                   | —                                          | —                 | —                 | —                                          |                               |               |               |                                            |                               |
| 13      | —                                        | —                                 | —                      | —                      | —                                          | —                 | —                 | —                                          |                               |               |               |                                            |                               |
| 14      | 3                                        | 2                                 | Neg                    | Neg                   | Neg                                        | Pos               | 90–100                                     | 3                             | Neg           | Pos           | 90–100                                     | 83                            |
| 15      | 5                                        | 2                                 | Neg                    | Neg                   | Neg                                        | Pos               | Pos               | 90–100                                     | 9                             |               |               |                                            |                               |
| 16      | 9                                        | 2                                 | Neg                    | Neg                   | Neg                                        | Pos               | 90–100                                     | 12                            |               |               |                                            |                               |
| 17      | —                                        | —                                 | —                      | —                      | —                                          | Neg               | Pos               | 90–100                                     | —                             |               |               |                                            |                               |
| 18      | 2                                        | 0                                 | Neg                    | Neg                   | Neg                                        | Neg               | Pos               | 80–90                                      | 43                            |               |               |                                            |                               |
| 19      | 3                                        | 3                                 | Neg                    | Neg                   | —                                          | —                 | —                 | —                                          |                               |               |               |                                            |                               |
| 20      | 8                                        | 7                                 | Neg                    | Neg                   | —                                          | —                 | —                 | —                                          |                               |               |               |                                            |                               |
| 21      | 6                                        | 3                                 | Neg                    | Neg                   | Neg                                        | Pos               | 90–100                                     | 4                             |               |               |                                            |                               |
| 22      | —                                        | —                                 | —                      | —                      | —                                          | Neg               | Pos               | 90–100                                     | —                             |               |               |                                            |                               |
| 23      | 0                                        | 0                                 | Neg                    | Neg                   | Neg                                        | Neg               | Pos               | 90–100                                     | 15                            | Neg           | Pos           | 90–100                                     | 25                            |
| 24      | 4                                        | 3                                 | Neg                    | Neg                   | Pos                                        | Pos               | Pos               | 90–100                                     | 7                             |               |               |                                            |                               |
| 25      | 7                                        | 1                                 | Neg                    | Neg                   | Neg                                        | Neg               | Pos               | 90–100                                     | 7                             |               |               |                                            |                               |
| 26      | 4                                        | (1)                               | Neg                    | Neg                   | Pos                                        | Pos               | 90–100                                     | 6                             |               |               |                                            |                               |
| 27      | 10                                       | 2                                 | Neg                    | Neg                   | Neg                                        | Pos               | 90–100                                     | 3                             | Neg           | Pos           | 90–100                                     | 11                            |
| No mAb (N=13) |                                         |                                    |                        |                        |                                            |                   |                   |                                            |                               |               |               |                                            |                               |
| 1       | 15                                       | 1                                 | Neg                    | Neg                   | Neg                                        | Pos               | 10–20                                        | 55                           |               |               |                                            |                               |
| 2       | 16                                       | 11                                | Pos                    | Pos                   | 20–30                                       |                   |                   |                                            |                               |               |               |                                            |                               |
| 3       | 19                                       | 15                                | Pos                    | Pos                   | 10–20                                       | Pos               | Pos               | 10–20                                      | 8                             | Pos           | Pos           | 10–20                                      | 15                            |
| 4       | 35                                       | 29                                | Pos                    | Pos                   | 10–20                                       |                   |                   |                                            |                               |               |               |                                            |                               |
| 5       | 7                                        | 7                                 | Neg                    | Neg                   | Pos                                        | Pos               | 10–20                                        | 12                           |               |               |                                            |                               |
| 6       | 13                                       | 9                                 | Neg                    | Neg                   | Pos                                        | Pos               | <10                                           | 14                           |               |               |                                            |                               |
| 7       | 14                                       | 13                                | Neg                    | Neg                   | Pos                                        | Neg               | 68                                           |                               |               |               |                                            |                               |
| Patient | Symptoms Onset to Initial Serology, days | Diagnosis to Initial Serology, days | Initial SARS-CoV-2 IgM | Initial SARS-CoV-2 IgG | Angiotensin-Converting Enzyme 2 Blocking Activity, % | Next SARS-CoV-2 IgM | Next SARS-CoV-2 IgG | Angiotensin-Converting Enzyme 2 Blocking Activity, % | Time Between Serologies, days | Last SARS-CoV-2 IgM | Last SARS-CoV-2 IgG | Angiotensin-Converting Enzyme 2 Blocking Activity, % | Time from Initial Serology, days |
|---------|------------------------------------------|------------------------------------|------------------------|------------------------|------------------------------------------------|----------------------|----------------|-----------------------------------------------|--------------------------------|----------------|----------------|------------------------------------------------|---------------------------------|
| 8       | 27                                      | 13                                 | Pos                    | Pos                    | 90–100                                         |                     |                |                                               |                                |                |                |                                               |                                 |
| 9       | 12                                      | 9                                  | Pos                    | Pos                    | 60–70                                         |                     |                |                                               |                                |                |                |                                               |                                 |
| 10      | 5                                       | 2                                  | Neg                    | Neg                    |                                               |                     |                | Neg                                           | Pos                             |                |                |                                               | 10–20                            |
| 11      | 25                                      | 14                                 | Pos                    | Pos                    | 40–50                                         |                     |                |                                               |                                |                |                |                                               |                                 |
| 12      | 117                                     | 115                                | Neg                    | Pos                    | 40–50                                         |                     |                |                                               |                                |                |                |                                               |                                 |
| 13      | 68                                      | 58                                 | Neg                    | Neg                    |                                               |                     |                |                                               |                                |                |                |                                               |                                 |

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; neg, negative; —, no data available; pos, positive.

aBamlanivimab or casirivimab-imdevimab.
patients who received either bamlanivimab or casirivimab-imdevimab with available postinfusion testing had measurable anti-SARS-CoV-2 IgG at the highest level of ACE2 receptor blocking activity detectable (90%–100%). In contrast, only one patient in the comparison group developed a similar level of ACE2 receptor blocking activity from natural immunity. Ten of the 13 patients in the comparison group eventually developed anti-SARS-CoV-2 IgM, and one of the four did not have detectable anti-SARS-CoV-2 IgM and IgG at day 58 postdiagnosis. This rate of seroenconsistency is consistent with reported findings of 51%–67% anti-SARS-CoV-2 IgG seropositivity in kidney transplant recipients with confirmed positive SARS-CoV-2 RT-PCR (23,24). Only one patient in the mAb group was seropositive for anti-SARS-CoV-2 IgM and IgG at first testing, compared with six of 13 patients in the non-mAb group. This may have been due to an earlier time of testing from symptom onset (median of 5 versus 18 days) in the mAb-treated versus nontreated groups. However, only five of 22 patients who received mAbs on subsequent testing had detectable anti-SARS-CoV-2 IgM antibodies. One possible explanation is that the early administration of either bamlanivimab or casirivimab-imdevimab impaired the host immune response by either reducing SARS-CoV-2 viral load or by directly inhibiting the virus-host immune interaction, resulting in a lower seroconversion rate. A better understanding of the stability and decay of bamlanivimab and casirivimab-imdevimab may be important when considering timing of subsequent vaccination against COVID-19.

The demonstration of high ACE2 receptor blocking activity against SARS-CoV-2 achieved with bamlanivimab and casirivimab-imdevimab in our patient cohort additionally raises the possibility of using neutralizing antibodies for immunoprophylaxis in the peritransplant period, particularly in the context of emerging knowledge of the poor response to SARS-CoV-2 vaccination in the transplant patient population (21,25–28). In transplant patients with negative SARS-CoV-2 antibody titer after two doses of mRNA vaccine, humoral response to a third vaccine dose remained disappointing (29). Beginning June 30, 2021, the FDA has now expanded authorization for casirivimab-imdevimab to be given as postexposure prophylaxis for patients who are at high risk for progression to severe disease and either (1) not fully vaccinated, or (2) immunocompromised patients who are not expected to mount adequate immune response to complete SARS-CoV-2 vaccination and who have exposure to individuals who tested positive for COVID-19.

Our study has several strengths, including a sizable number of transplant recipients treated with bamlanivimab and casirivimab-imdevimab under the EUA, pre- and postinfusion serologic monitoring, availability of a functional quantitative antibody assay, and an untreated group in whom COVID-19 serologic testing was available for comparison. However, our study has several limitations. It is a nonrandomized, noncontrolled, observational, single-center study. The comparison group is not matched, which limits generalization. Specifically, some patients in the comparison group did not come to our attention until later in their illness and did not receive mAb treatment because they were outside of the 10-day symptom onset window for administration of the mAb. There was a greater number of Hispanic/Latino patients in the comparison group (75%) than the mAb group (33%), and Hispanic/Latino patients have been reported to have greater odds of COVID-19-related hospitalization and death, even after adjusting for socioeconomic differences (30). Another limitation is that we were unable to further trend the ACE2 receptor blocking activity levels because our patients started getting vaccinated against SARS-CoV-2 in March 2021. Comparing passive immunity to the intensity of adaptive immunity is limited, because other aspects of the immune response were not evaluated. Despite these limitations, comparison between the two groups could remain valuable because the patients without neutralizing antibody intervention may illustrate the natural evolution of the disease in this patient population.

In this review of our experience, we found the use of bamlanivimab and casirivimab-imdevimab under the EUA criteria to be safe and associated with favorable outcomes for the treatment of mild to moderate COVID-19 after kidney transplantation.

Disclosures
A.X. Wang reports receiving research funding from CareDx. S. Busque reports receiving honoraria from Genentech; having consultancy agreements with, and serving as a scientific advisor for, or member of, Genentech and Gigagen; and having ownership interest in Gigagen. G.M. Chertow reports having consultancy agreements with Akebia, Amgen, Ardelyx, AstraZeneca, Baxter, Cricket, DiaMedica, Gilead, Miromatrix, Reata, Sanofi, Unicycive, and Vertex; serving on data safety monitoring boards for Angion, Bayer, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and ReCor; having ownership interest in ArdeIys, CloudCath, Durect, DxNow, Eliaz Therapeutics, Outset, Physiowave, and PuraCath; serving as coeditor of Brouwer & Rector’s The Kidney (Elsevier) and on the board of directors for Satellite Healthcare; and receiving research funding from the NIDDK and National Institute of Allergy and Infectious Diseases (NIAID). C.R. Lenihan reports receiving research funding from Astellas and CareDx, and honoraria from Veloxis. J.D. Scandling reports serving as a scientific advisor for, or member of, AlloVir; receiving

Figure 1. | High and sustained anti-SARS-CoV-2 IgG ACE2 blocking activity on early and late serologic testing in patients treated with mAb compared to non-mAb treated patients. ACE2, angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
research funding and honoraria from CareDx; and having consultancy agreements with Horizon Pharma. U. Singh reports serving as a scientific advisor for, or member of, Gilead; and receiving honoraria from Gilead and Regeneron. All remaining authors have nothing to disclose.

Funding
This work was supported by the Division of Intramural Research, NIAID grant 1R25AI147369-01 (to A.X. Wang).

Authors Contributions
S. Busque, G.M. Chertow, J. Kuo, C.R. Lenihan, K. Rööltgen, J.D. Scandling, and A.X. Wang reviewed and edited the manuscript; S. Busque and C.R. Lenihan provided supervision; S. Busque, C.R. Lenihan, and A.X. Wang were responsible for formal analysis; S. Busque and A.X. Wang conceptualized the study; G.M. Chertow and U. Singh were responsible for funding acquisition; J. Kuo was responsible for resources; J. Kuo, C.R. Lenihan, and A.X. Wang were responsible for project administration; C.R. Lenihan and A.X. Wang were responsible for investigation and validation; B.A. Pinsky, K. Rööltgen, and A.X. Wang were responsible for methodology; and A.X. Wang wrote the original draft, and was responsible for data curation, software, and visualization.

Supplemental Material
This article contains supplemental material online at http://kidney360.asnjournals.org/lookup/suppl?doi=10.34067/KID.0005732011/-/DCSupplemental. Supplemental Table 1. Bamlanivimab and casirivimab-imdevimab emergency use authorization.

References
1. Horby P, Lim WS, Emberson JR, Mahtam M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmalı E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ; RECOVERY Collaborative Group: Dexamethasone in hospitalised patients with Covid-19—Preliminary report. N Engl J Med 384: 693–704, 2021
2. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Bell JL, Linsell L, Mitchell S, Morens DM, Nelson JA, Pfaller MA, Zeng H, Menegus MA, Rellschaft A, Hwang C, Hamer DH, Longo DL, Remis RS, Whitley RJ, Whitley RJ: Remdesivir and convalescent plasma for the treatment of Covid-19. N Engl J Med 383: 1813–1826, 2020
3. Akalin E, Azzi Y, Battash K, Seetharamajju H, Parides M, Hemedige V, Ross M, Forest S, Goldstein YD, Ajajmi M, Litano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Roca J, Kinkhabwala M: Covid-19 and kidney transplantation. N Engl J Med 382: 2475–2477, 2020
4. Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, Sala K, Kotton CN, Blumberg EA, Besharatian BD, Tanna SD, Jison MG, Malinis M, Azar MM, Rakita RM, Morillas JA, Majeed A, Sait AS, Spaggiari M, Hemedige V, Mehta SA, Neumann H, Baradari A, Goldman JD, Lala A, Hemmersbach-Miller M, McCort ME, Bajrovic V, Ortiz-Bautista C, Friedman-Moraco R, Sehgal S, Lease ED, Fisher CE, Limaye AP; UW COVID-19 SOT Study Team: COVID-19 in solid organ transplant: A multi-center cohort study [published online ahead of print August 7, 2020]. Clin Infect Dis 10:1093/cid/ciaa1097
5. Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, Gatault P, Thauvat O, Legris T, Fritat L, Westeel PF, Goutaudier V, Ildidou M, Smanoudi R, Colosio C, Sicard A, Bertrand D, Mousson C, Bamoulid J, Masset C, Thierry A, Couzi L, Chemouny JM, Duaveau V, Moal V, Blanco G, Grimbert P, Durrbach A, Moulin B, Angelache D, Ruch Y, Kaeufcer C, Benotmane I, Solis M, LeMureur Y, Hazzan M, Danion F; French SOT COVID Registry: Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant 21: 1295–1303, 2020
6. Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, Redondo-Pachón MD, Murphy B, Florman S, Cyrino LG, Grafals M, Venkataraman S, Cheng XS, Wang AX, Zaza G, Ranghino A, Furián L, Mansière J, Maggiore U, Gandolfino I, Agrawal N, Patel H, Akalin E, Rielia LV: COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. Am J Transplant 20: 3140–3148, 2020
7. Wang AX, Quintero Cardona O, Ho DY, Busque S, Lenihan CR: Influence of immunosuppression on seroconversion against SARS-CoV-2 in two kidney transplant recipients. Transplant Infect Dis 23: e13423, 2021
8. Zhang W, Davis BD, Chen SS, Sincir Martinez JM, Plummer JT, Vail E: Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA 325: 1324–1326, 2021
9. Marovich M, Mascola JR, Cohen MS: Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 324: 131–132, 2020
10. Lilly: Bamlanivimab antibody playbook, 2020. Available at: https://www.covid19.lilly.com/assets/pdf/bamlanivimab/lilly-antibodies-playbook.pdf. Accessed February 17, 2021
11. US Food and Drug Administration: FDA letter of authorization for the EUA of casirivimab with imdevimab. Available at: https://www.regeneron.com/downloads/treatment-covid19-eua-fda-letter.pdf. Accessed August 29, 2021
12. European Medicines Agency: EMA conditions of use for unauthorised bamlanivimab. Available at: https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-limited-antibody-combination-bamlanivimab/etesevimab-cov2-19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted_en.pdf. Accessed April 19, 2021
13. European Medicines Agency: EMA conditions of use for unauthorised casirivimab and imdevimab. Available at: https://www.ema.europa.eu/en/documents/referral/regn-cov2-antibody-combination-casirivimab/imdevimab-cov2-19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted_en.pdf. Accessed April 19, 2021
14. US Food and Drug Administration: Fact sheet for healthcare providers emergency use authorization (EUA) of Bamlanivimab. Available at: https://www.fda.gov/media/143603/download. Accessed February 17, 2021
15. Stanford Health Care: Stanford virology lab COVID-19 PCR & serology statistics. Available at: https://stanfordhealthcare.org/stanford-health-care-now/2020/novel-coronavirus/stanford-virology-lab-covid19-2020-PCR-statistics.html. Accessed February 17, 2021
16. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Naejeb J, Hunter M, Wang H, Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otebro-Cardoso AR, Pham TD, Rastogi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL, Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA, Boyd SD: Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 5(46): eabe0240, 2020 https://doi.org/10.1126/sciimmunol.abf0240
17. Kidney Disease Improving Global Outcomes: KDIGO clinical practice guideline for acute kidney injury. Available at https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf.
18. Cohen MS: Monoclonal antibodies to disrupt the progression of COVID-19 SARS-CoV-2 in two kidney transplant recipients. Transplant Infect Dis 23: e13423, 2021
Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampingman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipschitz L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 384: 238–251, 2021 https://doi.org/10.1056/NEJMoa2035002

20. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shibolet O, Levy S, Houri I, Baruch R, Katchman H: Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 21: 2719–2726, 2021 https://doi.org/10.1111/ajt.16615

21. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM: Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 325: 1784–1786, 2021 https://doi.org/10.1101/jama.2021.0202

22. Dhand A, Lobo SA, Wolfe K, Feola N, Lee L, Nog R, Chen D, Glicklich D, DiFlorio T, Nabors C: Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation 105: e68–e69, 2021 https://doi.org/10.1097/TP.0000000000003737

23. Burack D, Pereira MR, Tsapepas DS, Harren P, Farr MA, Arcasoy S, Cohen DJ, Mohan S, Emond JC, Hod EA, Verna EC: Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant patients with confirmed infection. Am J Transplant 21: 2254–2261, 2021 https://doi.org/10.1111/ajt.16541

24. Prendergast M, Clarke C, Gleeson S, Greathhead L, Santos E, McLean A, Randell P, Moore LSP, Mughal N, Guckian M, Kelleher P, McAdoo SP, Williscombe M: Detection of SARS-CoV-2 antibodies in kidney transplant recipients. J Am Soc Nephrol 31: 2753–2756, 2020 https://doi.org/10.1681/ASN.2020081152

25. Resende MR, Husain S, Gubbay J, Singer L, Cole E, Renner EL, Rotstein C: Low seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipients. Can J Infect Dis Med Microbiol 24: e7–e10, 2013 https://doi.org/10.1155/2013/256756

26. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T: Serologic vaccination response after solid organ transplantation: A systematic review. PLoS One 8: e56974, 2013 https://doi.org/10.1371/journal.pone.0056974

27. Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykman Y, Shibolet O, Levy S, Houri I, Baruch R, Katchman H: Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 21: 2719–2726, 2021 https://doi.org/10.1111/ajt.16615

28. Marinaki S, Gavrioulopolos S, Degiannis D, Roussos S, Pavlopoulos ID, Hatzakis A, Boletis IN: Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am J Transplant 21: 2913–2915, 2021 https://doi.org/10.1111/ajt.16607

29. Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, Segev DL: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: A case series. Ann Intern Med 174: 1330–1332, 2021 https://doi.org/10.7326/L21-0282

30. Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB: Racial and ethnic disparities in SARS-CoV-2 testing and COVID-19 outcomes in a Medicaid managed care cohort. Am J Prev Med 61: 644–651, 2021

Received: September 1, 2021 Accepted: October 15, 2021
See related editorial, “Durable Protection after Anti-SARS-CoV2 Monoclonal Antibody Therapy,” on pages 8–10.